Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
J Cancer Res Clin Oncol. 2023 Aug;149(10):7933-7944. doi: 10.1007/s00432-023-04673-7. Epub 2023 Mar 9.
The bridging integrator 1 (BIN1) protein was originally identified as a pro-apoptotic tumor suppressor that binds to and inhibits oncogenic MYC transcription factors. BIN1 has complex physiological functions participating in endocytosis, membrane cycling, cytoskeletal regulation, DNA repair deficiency, cell-cycle arrest, and apoptosis. The expression of BIN1 is closely related to the development of various diseases such as cancer, Alzheimer's disease, myopathy, heart failure, and inflammation.
Because BIN1 is commonly expressed in terminally differentiated normal tissues and is usually undetectable in refractory or metastatic cancer tissues, this differential expression has led us to focus on human cancers associated with BIN1. In this review, we discuss the potential pathological mechanisms of BIN1 during cancer development and its feasibility as a prognostic marker and therapeutic target for related diseases based on recent findings on its molecular, cellular, and physiological roles.
BIN1 is a tumor suppressor that regulates cancer development through a series of signals in tumor progression and microenvironment. It also makes BIN1 a feasible early diagnostic or prognostic marker for cancer.
桥连整合因子 1（BIN1）蛋白最初被鉴定为一种促凋亡的肿瘤抑制因子，它能与致癌 MYC 转录因子结合并抑制其活性。BIN1 具有复杂的生理功能，参与内吞作用、膜循环、细胞骨架调节、DNA 修复缺陷、细胞周期停滞和细胞凋亡。BIN1 的表达与多种疾病的发展密切相关，如癌症、阿尔茨海默病、肌病、心力衰竭和炎症。
由于 BIN1 在终末分化的正常组织中普遍表达，而在难治性或转移性癌症组织中通常检测不到，这种差异表达使我们专注于与 BIN1 相关的人类癌症。在这篇综述中，我们根据 BIN1 在分子、细胞和生理水平上的作用的最新发现，讨论了 BIN1 在癌症发展过程中的潜在病理机制及其作为相关疾病的预后标志物和治疗靶点的可行性。
BIN1 是一种肿瘤抑制因子，通过肿瘤进展和微环境中的一系列信号调节癌症的发展。这也使得 BIN1 成为癌症早期诊断或预后标志物的一种可行选择。
